A new publication in Acta Materia Medica journal addresses the challenges of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in cancer treatment. The authors conducted a network meta-analysis of 55 randomized controlled trials involving 32,522 patients to rank the safety of various ICI therapies. They found that ICIs increase the risk of endocrine toxicities, with dual ICI regimens posing a greater risk. Specifically, CTLA-4 inhibitors like ipilimumab are associated with hypophysitis, while PD-1/PD-L1 inhibitors like pembrolizumab and nivolumab predispose patients to thyroid-related dysfunction. This study provides important evidence for optimizing the risk-benefit balance of ICI therapies in clinical practice.
Source link
Comprehensive analysis of immune checkpoint inhibitors reveals endocrine toxicity patterns
